This is a voluntary research study to evaluate the effects of an investigational medication on Alzheimer’s disease (AD). People who are interested in participating will be screened for probable AD or mild cognitive impairment to see if they qualify. This study could last between 1.5 to 3.5 years, depending on how long participants choose to remain in the clinical trial. Participants are monitored for safety and cognitive function throughout the trial. Genentech, Inc., a member of the Roche Group, is sponsoring this research study.
What is the purpose of the Genentech Alzheimer’s disease study?
The purpose of this study is to evaluate the safety and effectiveness of the investigational drug, RO7105705, in eligible participants with prodromal to mild AD. Participants will be randomly assigned (like flipping a coin) to receive either RO7105705 or a placebo to compare their effects on AD. A placebo is an inactive substance that looks like RO7105705, but has no effect. The investigational drug will be administered intravenously (in your vein) at various time points during the study. RO7105705 has been previously studied in people with AD in a smaller study conducted in the United States.
This is a voluntary research study for people ages 50-80 years old. Everyone undergoes the Informed Consent process, during which time people can agree to participate in the study or not. Those who agree to participate in this study will undergo testing and evaluation by the study doctor for probable AD or mild cognitive impairment to see if they qualify for the study. All qualified participants must have a study partner with whom they spend regular time and would be able to support them through the duration of the study.
To learn more about the Genentech Alzheimer’s disease study, please call (401) 455-6402 or send an e-mail email@example.com. Ask about the “Genentech Alzheimer’s Trial.”